157 related articles for article (PubMed ID: 27055285)
21. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
[TBL] [Abstract][Full Text] [Related]
22. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
23. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
[TBL] [Abstract][Full Text] [Related]
25. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia.
Kallel I; Khabir A; Boujelbene N; Abdennadher R; Daoud J; Frikha M; Aifa S; Sallemi-Boudawara T; Rebaï A
J Recept Signal Transduct Res; 2012 Jun; 32(3):142-9. PubMed ID: 22394363
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
[TBL] [Abstract][Full Text] [Related]
27. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
28. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
31. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
32. Increased concentrations of growth factors and activation of the EGFR system in breast cancer.
Olsen DA; Bechmann T; Østergaard B; Wamberg PA; Jakobsen EH; Brandslund I
Clin Chem Lab Med; 2012 Oct; 50(10):1809-18. PubMed ID: 23089711
[TBL] [Abstract][Full Text] [Related]
33. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.
Gonzalez-Conchas GA; Rodriguez-Romo L; Hernandez-Barajas D; Gonzalez-Guerrero JF; Rodriguez-Fernandez IA; Verdines-Perez A; Templeton AJ; Ocana A; Seruga B; Tannock IF; Amir E; Vera-Badillo FE
Cancer Treat Rev; 2018 Jan; 62():1-8. PubMed ID: 29126017
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
37. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
39. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma.
Zhu Z; Yu W; Fu X; Sun M; Wei Q; Li D; Chen H; Xiang J; Li H; Zhang Y; Zhao W; Zhao K
J Exp Clin Cancer Res; 2015 Sep; 34(1):95. PubMed ID: 26338103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
